Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Alternatively activated neutrophils limit T cell-driven neuroinflammation.

Journal of neuroinflammation·2026

Same author

Tumor immunogenicity shapes CNS immune niches and CD8⁺ T cell fate in glioblastoma.

Journal of neuroinflammation·2026

Same author

Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach.

Frontiers in immunology·2025

Same author

A mini review of leveraging biobanking in the identification of novel biomarkers in neurological disorders: insights from a rapid single-cell sequencing pipeline.

Frontiers in neuroscience·2025

Same author

Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial.

The Lancet. Neurology·2024

Same author

Editorial: CNS myeloid cell function in health and disease.

Frontiers in immunology·2024

Search research articles

Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

Stage-specific immune dysregulation in multiple sclerosis.

Benjamin M Segal¹

¹Holtom-Garrett Program in Neuroimmunology and Multiple Sclerosis Center, Department of Neurology, University of Michigan , Ann Arbor, Michigan.

Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research

|August 2, 2014

Summary

Identifying immunological biomarkers in multiple sclerosis (MS) is crucial. This review focuses on stage-specific biomarkers to predict disease course and treatment response, aiding clinical management.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

Related Experiment Videos

Last Updated: Apr 26, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

Area of Science:

Neuroimmunology
Autoimmune Diseases

Background:

Multiple sclerosis (MS) is an autoimmune disease initiated by T-helper 1 (Th1) and Th17 cells targeting myelin.
MS progression involves relapsing-remitting and secondary progressive (SP) phases, with unclear transition mechanisms and debated inflammation roles in SP.
Current lack of predictive immunological biomarkers hinders MS management and clinical trial efficiency.

Purpose of the Study:

To review existing literature on immunological biomarkers in MS.
To highlight stage-specific differences and similarities in these biomarkers.
To emphasize the need for biomarkers predictive of clinical course and treatment response.

Main Methods:

Literature review of immunological biomarkers in multiple sclerosis.
Focus on stage-specific (relapsing-remitting vs. secondary progressive) analyses.
Discussion of biomarker relevance to disease progression and therapeutic responsiveness.

Main Results:

No definitive immunological biomarkers currently predict MS clinical course, lesion development, or disability.
Understanding stage-specific immune responses is critical for biomarker discovery.
Inflammation's role in the secondary progressive phase remains an active area of research.

Conclusions:

Development of reliable immunological biomarkers is essential for personalized MS treatment and improved clinical trials.
Stage-specific biomarkers could differentiate disease phases and predict patient outcomes.
Further research is needed to identify and validate biomarkers for effective MS management.